Cancer Treatment Today

There is ongoing trial: FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma, NCT02023593.

Although there are no standard second-line treatment for metastatic esophageal carcinoma, some studies have showed that irinotecan, fluorouracil may be effective in treating patients with metastatic esophageal carcinoma after failure of first-line treatment. Since irinotecan, fluorouracil, and leucovorin work in different ways to stop the growth of tumor. Giving more than one drug may be more effective.

There is ongoing trial: FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma, NCT02023593.

Although there are no standard second-line treatment for metastatic esophageal carcinoma, some studies have showed that irinotecan, fluorouracil may be effective in treating patients with metastatic esophageal carcinoma after failure of first-line treatment. Since irinotecan, fluorouracil, and leucovorin work in different ways to stop the growth of tumor. Giving more than one drug may be more effective. In this phase  trial, the investigator would like to observe the efficacy and safety of FOLFIRI(Irinotecan/5-FU/leucovorin ) as second-line treatment for metastatic esophageal carcinoma.

Ferte C1, Romano O, Mariette C, Bourgeois V, Peugniez C, Lindet C, Ladrat L, Triboulet JP,

Hebbar, M.FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.J Chemother. 2011 Dec;23(6):358-61.

David H. Ilson, Esophageal Cancer Chemotherapy: Recent Advances. Gastrointest Cancer Res. 2008 Mar-Apr; 2(2): 8592.